Envestnet Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Envestnet Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$738K	Sell	201,026 -29,086	-13%	-$96.8K	﹤0.01%	3821
2026 Q1	$706K	Buy	230,112 +108,669	+89%	+$420K	﹤0.01%	3687
2025 Q4	$497K	Sell	121,443 -53,672	-31%	-$266K	﹤0.01%	3700
2025 Q3	$855K	Sell	175,115 -14,786	-8%	-$77.7K	﹤0.01%	3420
2025 Q2	$961K	Sell	189,901 -15,992	-8%	-$78.6K	﹤0.01%	3301
2025 Q1	$1.09M	Sell	205,893 -25,863	-11%	-$189K	﹤0.01%	3145
2024 Q4	$1.57M	Buy	231,756 +11,646	+5%	+$78.3K	﹤0.01%	2845
2024 Q3	$1.45M	Buy	220,110 +75,974	+53%	+$545K	﹤0.01%	2882
2024 Q2	$1.08M	Buy	144,136 +10,216	+8%	+$89.1K	﹤0.01%	2987
2024 Q1	$1.34M	Buy	133,920 +6,480	+5%	+$72.2K	﹤0.01%	2827
2023 Q4	$1.26M	Buy	+127,440	New	+$909K	﹤0.01%	2766

Other funds holding RXRX

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Carroll Investors Mt Pleasant, South Carolina $234M AUM 59.79% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Allen Operations New York $722M AUM 20.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Envestnet Asset Management's RXRX Position: Q2 2026 in Review

Envestnet Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q2 2026, selling an estimated $96.8K and leaving 201,026 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #3821.

Envestnet Asset Management first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.57M in Q4 2024. 124 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Envestnet Asset Management held 201,026 shares of Recursion Pharmaceuticals worth $738K as of Q2 2026.
Envestnet Asset Management sold 29,086 Recursion Pharmaceuticals shares in Q2 2026, an estimated $96.8K.
Recursion Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3821 holding.
Envestnet Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Envestnet Asset Management's Recursion Pharmaceuticals position peaked at $1.57M in Q4 2024.
124 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.